Home About us Editorial board Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 67
  • Home
  • Print this page
  • Email this page
Year : 2013  |  Volume : 20  |  Issue : 4  |  Page : 299-304

Iron status and benefit of the use of parenteral iron therapy in pre-dialysis Chronic Kidney Disease patients

Department of Medicine, Obafemi Awolowo University, Ile-Ife; P.M.B 5538 Ile-Ife, Osun State, Nigeria

Correspondence Address:
F A Arogundade
Department of Medicine, Obafemi Awolowo University / Teaching Hospitals Complex, P.M.B 5538 Ile-Ife, Osun State
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Aims and objectives: Anaemia is a major cardiovascular risk factor in chronic kidney disease (CKD). Treatment and correction of anaemia leads to im- provement of cardiovascular status and quality of life of patients with CKD. This interventional open labeled randomised controlled study comparing the effect of intravenous and oral iron therapy in improving red cell indices and iron status in anaemic pre-dialysis Chronic Kidney Disease was carried out to determine iron status in anaemic pre-dialysis CKD patients to assess the benefit of parenteral iron supplementation as against empirical oral iron in CKD patients with iron deficiency. Patients and Methods: Sixty consecutive pre-dialysis chronic kidney disease patients attending the renal clinic over a six month period were screened. Forty- one subjects (68.3%) were found to be anaemic and were subsequently studied. Results: The ages of the patients ranged between 19 and 71 years with a mean age of 39years. The mean serum creatinine and mean creatinine clear- ance were 201.80 (±70.25)μmol/L and 37.90 (±12.17)ml/minute respectively. The haematocrit concentration was found to correlate inversely with the level of serum creatinine and 56.1% of the anaemic patients had iron defi- ciency. The mean PCV rise in the intravenous iron group was 2.42 (±1.98)% and this was statistically significant (p=0.002) while the mean PCV differ- ence was 0.909 (±0.94)% in the oral iron group. Intravenously administered iron alone permitted anaemia correction in about one-third of these patients without any life threatening adverse drug event. Conclusion:Anaemia is very common in the pre-dialysis CKD population and the prevalence of iron deficiency is high. Intravenous iron supplementa- tion is an effective and safe treatment for the anaemia in the pre-dialysis CKD patients. Response to oral iron was poor.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal